Novel alternative methods for the delivery of drugs for the treatment of asthma
- PMID: 12842601
- DOI: 10.1016/s0169-409x(03)00078-4
Novel alternative methods for the delivery of drugs for the treatment of asthma
Abstract
Successful delivery of dry powder aerosols to the lung requires careful consideration of the powder production process, formulation and inhaler device. Newer production methods are emerging to prepare powders with desirable characteristics for inhalational administration. The conventional formulation approach of adding coarse lactose carriers to the drug to form binary powder systems to enhance powder flow and dispersion properties has been expanded to using finer carrier particles and hydrophobic materials, as well as ternary systems. Particle morphology and surface properties have also been explored to enhance powder performance. For the inhaler device, the new generation inhalers are designed to reduce or completely decouple the influence of air flow on the aerosol generation. Each of these determinants for powder aerosol delivery is reviewed with a strong focus on the patent literature that contains enormous information about the latest development in this field.
Similar articles
-
The role of particle properties in pharmaceutical powder inhalation formulations.J Aerosol Med. 2002 Fall;15(3):325-30. doi: 10.1089/089426802760292672. J Aerosol Med. 2002. PMID: 12396421 Review.
-
A review of co-milling techniques for the production of high dose dry powder inhaler formulation.Drug Dev Ind Pharm. 2017 Aug;43(8):1229-1238. doi: 10.1080/03639045.2017.1313858. Epub 2017 Apr 19. Drug Dev Ind Pharm. 2017. PMID: 28367654
-
Development of dry powder inhalers.Recent Pat Drug Deliv Formul. 2007;1(1):11-21. doi: 10.2174/187221107779814159. Recent Pat Drug Deliv Formul. 2007. PMID: 19075871 Review.
-
Inhalation therapy: technological milestones in asthma treatment.Adv Drug Deliv Rev. 2003 Jul 18;55(7):779-91. doi: 10.1016/s0169-409x(03)00077-2. Adv Drug Deliv Rev. 2003. PMID: 12842600 Review.
-
Evolution of dry powder inhaler design, formulation, and performance.Respir Med. 2002 May;96(5):293-304. doi: 10.1053/rmed.2001.1276. Respir Med. 2002. PMID: 12113378 Review.
Cited by
-
In Vivo Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles.Mol Pharm. 2017 Dec 4;14(12):4741-4750. doi: 10.1021/acs.molpharmaceut.7b00532. Epub 2017 Nov 9. Mol Pharm. 2017. PMID: 29068693 Free PMC article.
-
State of the Art in Capsule-Based Dry Powder Inhalers: Deagglomeration Techniques and the Consequences for Formulation Aerosolization.Pharmaceutics. 2022 May 31;14(6):1185. doi: 10.3390/pharmaceutics14061185. Pharmaceutics. 2022. PMID: 35745758 Free PMC article.
-
The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.Pharm Res. 2006 Aug;23(8):1665-74. doi: 10.1007/s11095-006-9012-7. Pharm Res. 2006. PMID: 16845584 Review.
-
Physical stability of dry powder inhaler formulations.Expert Opin Drug Deliv. 2020 Jan;17(1):77-96. doi: 10.1080/17425247.2020.1702643. Epub 2019 Dec 13. Expert Opin Drug Deliv. 2020. PMID: 31815554 Free PMC article. Review.
-
Production of ultrafine sumatriptan succinate particles for pulmonary delivery.Pharm Res. 2008 Sep;25(9):2012-8. doi: 10.1007/s11095-008-9586-3. Epub 2008 Jun 26. Pharm Res. 2008. PMID: 18581210
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical